Clinical trials: Visual Fields
Glaucoma
Vision Restoration Training in Glaucoma
Importance: Visual field loss after retinal damage in glaucoma is considered irreversible and methods are needed to achieve vision restoration.
- Trial name
- gVRT (NCT01799707)
- Testing
- vision restoration training, Discrimination Training
- Volunteers
- 30 people
- Sponsor
- University of Magdeburg
Visual Field
To Compare the Octopus 311 and the Humphrey Field Analyzer 700 Series
To compare the Octopus 311 and the HFA 700 series
- Trial name
- NCT00441194
- Testing
- Visual Field (Octopus 311 and the HFA 700 series)
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Haag Streit USA
Glaucoma
Determining the Clinical Utility of Using Virtual Reality Headsets to Assess Visual Function in Those With Glaucoma.
To validate a new virtual reality (VR) based visual field test against the gold standard clinical perimetry test (Humphrey Visual field test 24-2).
- Trial name
- NCT04273438
- Testing
- Visual field testing using Oculus Rift and Humphrey Visual Field Perimeter, Visual Field Testing using HUmphrey 24-3 Perimeter
- Where
- United Kingdom
- Volunteers
- 17 people
- Sponsor
- Queen's University, Belfast
Retinitis Pigmentosa, Stargardt Macular Dystrophy
Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)
The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision.
- Conditions
- Retinitis Pigmentosa, Stargardt Macular Dystrophy, Stargardt Disease, Geographic Atrophy From Age-related Macular Degeneration
- Trial name
- DEFINE-IRD (NCT07502664)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Ray Therapeutics, Inc.
Other Complications of Surgical and Medical Procedures
Comparison of the Effects of Nicardipine and Remifentanil on Surgical Visual Field
In the present study, the purpose was to compare the effects of Nicardipine and Remifentanil on surgical visual field and hemodynamic parameters in microscopic tympanomastoidectomy cases with Controlled Hypotension (CH).
- Trial name
- NCT06130527
- Testing
- Nicardipine, Remifentanil
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Erol Karaaslan
Glaucoma
Evaluation of Different Perimetric Grids to Detect Central Visual Field Defect in Glaucoma Patients With Reduce Ganglion Cell Layer Thickness Measured by Spectral Domain OCT.
The aim of the study is to evaluate the agreement between three different grids in detecting central visual field defect in early glaucoma patients with reduced ganglion cell layer thickness.
- Trial name
- NCT06227611
- Where
- 2 sites in Italy
- Volunteers
- 16 people
- Sponsor
- Fondazione G.B. Bietti, IRCCS
Dyslexia
Dyslexics' Visual Attention Field
dyslexia is often considered like a phonological deficit but some researches show that a visual attention (V-A) deficit can occur in dyslexia.
- Trial name
- NCT03285789
- Testing
- Passing tests in dyslexics with reduced eva, Passing tests in controls
- Where
- France
- Volunteers
- 1,460 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Primary Open Angle Glaucoma, Ocular Hypertension
Assessment of Optic Nerve Radiation in Patients With Glaucoma and Ocular Hypertension by 7 Tesla Diffusion Tensor Imaging
Glaucoma is among the leading causes for blindness in the western world. Elevated intraocular pressure (IOP) has been identified as the most important risk factor.
- Conditions
- Primary Open Angle Glaucoma, Ocular Hypertension, Normal Tension Glaucoma
- Trial name
- NCT01864317
- Testing
- 7-Tesla MRI, Optical Coherence Tomography, Heidelberg Retina Tomography
- Where
- Austria
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Relapsing Remitting Multiple Sclerosis, Optic Neuropathy
Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis
The objective of this trial is to assess the efficacy and safety of CNM-Au8 as a remyelinating treatment for vision-impairing MS lesions in participants who have chronic vision impairment as a result of Relapsing-Remitting…
- Conditions
- Relapsing Remitting Multiple Sclerosis, Optic Neuropathy, Optic; Neuritis, With Demyelination
- Trial name
- VISIONARY-MS (NCT03536559)
- Testing
- CNM-Au8
- Where
- 7 sites in United States, Australia and 1 more
- Volunteers
- 73 people
- Sponsor
- Clene Nanomedicine
Visual Fields Hemianopsia, Stroke, Ischemic
Repetitive Transcranial Magnetic Stimulation for Post-Stroke Visual Field Defects
Visual field defects (VFD) usually do not show improvement beyond 12 weeks from onset. Plasticity occurs in areas of residual vision (ARV) at the visual field which are the functional counterpart of partially damaged brain…
- Conditions
- Visual Fields Hemianopsia, Stroke, Ischemic, Stroke Hemorrhagic
- Trial name
- NCT04021160
- Testing
- High frequency repetitive transcranial magnetic stimulation (rTMS)
- Where
- Egypt
- Volunteers
- 32 people
- Sponsor
- Ain Shams University
Stroke, Ischemic, Quadrantanopia
Visual Rehabilitation After Occipital Stroke
This research aims to examine changes in plastic potential of the visual system with time from stroke affecting primary visual cortex.
- Conditions
- Stroke, Ischemic, Quadrantanopia, Vision Loss Partial, Visual Field Defect, Peripheral
- Trial name
- NCT04798924
- Testing
- Subacute Training in the intact field, Subacute Training in the blind field, Chronic Training in the blind field
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Rochester
Cortical Blindness, Stroke Ischemic
Mechanisms of Visual Restoration After Occipital Stroke
This project will collect brain imaging data to quantify the effects of early visual cortex damage and visual training interventions on the structure and function of the residual visual system.
- Conditions
- Cortical Blindness, Stroke Ischemic, Vision Loss Partial, Visual Fields Hemianopsia
- Trial name
- MOVROS (NCT07134777)
- Testing
- MRI
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Central Retinal Artery Occlusion
A Phase III Randomized, Blind, Double Dummy, Multicenter Study Assessing the Efficacy and Safety of IV THrombolysis (Alteplase) in Patients With acutE Central retInal Artery Occlusion
The aim of the THEIA study is to determine if Alteplase administrated within 4.5 hours improve visual deficit due to acute CRAO with a good safety profile.
- Trial name
- THEIA (NCT03197194)
- Testing
- Alteplase, acetylsalicylic acid
- Where
- 17 sites in France
- Volunteers
- 70 people
- Sponsor
- Nantes University Hospital
Glaucoma, Progression
Visual Field Progression and RNFL Change After PreserFlo MicroShunt Implantation
The trabeculectomy is the gold standard in glaucoma surgery, nevertheless often postoperative interventions have to be done. (1),(2) The PreserFlo MicroShunt (Santen, Osaka, Japan) implantation occurs without critical steps of…
- Conditions
- Glaucoma, Progression, Surgery
- Trial name
- NCT06174324
- Testing
- PreserFlo Microshunt
- Where
- Austria
- Volunteers
- 100 people
- Sponsor
- Klinikum Klagenfurt am Wörthersee
Age Related Macular Degeneration
Correlation Between Visual Field Defects on Foresee Preferential Hyperacuity Perimeter(PHP) and on Optical Coherence Tomography (OCT) in Patients With Choroidal Neovascularization (CNV)
Study come to investigate the correlation between visual fields (VF) defects map generated by preferential hyperacuity perimeter (PHP) and features of the choroidal neovascular lesions (CNV) demonstrated by Optical Coherence…
- Trial name
- PHP (NCT00692887)
- Testing
- PHP - Preferential Hyperacuity Perimeter (Foresee)
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Notal Vision Ltd.
Ocular Hypertension, Open Angle Glaucoma
Study of AR-13324 in Patients With Elevated Intraocular Pressure
In this double-masked, vehicle-controlled, dose-response study, subjects will be randomized to receive AR-13324 Ophthalmic Solution 0.01%, 0.02%, and 0.04% or its vehicle (one eye), once daily (QD)in the morning (AM) for 7 days.
- Trial name
- NCT01528787
- Testing
- AR-13324 Ophthalmic Solution 0.01%, AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.04%
- Where
- 11 sites in United States
- Volunteers
- 85 people
- Sponsor
- Aerie Pharmaceuticals
Age-Related Macular Degeneration, Geographic Atrophy
Optical Coherence Tomography and Microperimetry Biomarker Evaluation in Patients With Geographic Atrophy Study
This study is a biomarker evaluation study in patients with geographic atrophy secondary to age-related macular degeneration (AMD).
- Conditions
- Age-Related Macular Degeneration, Geographic Atrophy, Visual Field Defect, Central Scotoma of Both Eyes
- Trial name
- OMEGA (NCT05963646)
- Testing
- Natural history study
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- Institute of Molecular and Clinical Ophthalmology Basel
Stroke, Ischemic, Hemianopia, Homonymous
Statistical Learning as a Novel Intervention for Cortical Blindness
This project aims to develop a novel visual training paradigm for use in visually-intact participants and those sufferings from stroke-induced visual impairments.
- Conditions
- Stroke, Ischemic, Hemianopia, Homonymous, Hemianopsia, Occipital Lobe Infarct
- Trial name
- NCT06578117
- Testing
- Vision Training and Learning Task
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Hemianopsia
tDCS Associated to Blindsight Rehabilitation for the Treatment of Homonymous Hemianopsia
Homonymous hemianopia is one of the most common symptoms following a neurologic damage and has many negative effects on functional abilities and daily activities.
- Trial name
- TABRTHH (NCT02956668)
- Testing
- Blindsight Training associated to tDCS, Blindsight Training alone
- Where
- Italy
- Sponsor
- University of Milano Bicocca
Cognitive Change
PatiEnt Neuropsychological outcomeS After laseR Ablation
PatiEnt Neuropsychological outcomeS After laseR ablation
- Trial name
- PENSAR (NCT05075850)
- Testing
- Neuroblate System
- Where
- 7 sites in United States
- Volunteers
- 81 people
- Sponsor
- Monteris Medical